BIOA
BioAge Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+0.95%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.61
- Revenue estimate
- $1.5M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.58
- EPS estimate
- -$0.61
- Revenue actual
- $2.5M
- Revenue estimate
- $1.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +13.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $38
- PT range
- $35 – $40
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026